Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Forbes

Showing results (291-300 of 309) with videos related to

Pageof 31
Sort By:
Oncogene|September 25, 1998
EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survivalR Hui, J R Ball, R D Macmillan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2007
The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancerPer Karlsson, Bernard F Cole, Karen N Price, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2011
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trialG Viale, M M Regan, P Dell'Orto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2011
Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane studyJudith M Bliss, Lucy S Kilburn, Robert E Coleman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2008
Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trialDiana Crivellari, Zhuoxin Sun, Alan S Coates, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 16, 2007
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trialL Mauriac, A Keshaviah, M Debled, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2007
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98Alan S Coates, Aparna Keshaviah, Beat Thürlimann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancerMartin R Stockler, Vernon J Harvey, Prudence A Francis, et al.
Journal of Thrombosis and Haemostasis : JTH|July 9, 2021
Remote history of VTE is associated with severe COVID-19 in middle and older age: UK Biobank cohort studyJana J Anderson, Frederick K Ho, Claire L Niedzwiedz, et al.
British Journal of Cancer|April 20, 2016
Adjuvant ovarian function suppression and cognitive function in women with breast cancerKelly-Anne Phillips, Meredith M Regan, Karin Ribi, et al.
Pageof 31

Showing results (291-300 of 309) with videos related to

Sort By:
Pageof 31
Oncogene|September 25, 1998
EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survivalR Hui, J R Ball, R D Macmillan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2007
The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancerPer Karlsson, Bernard F Cole, Karen N Price, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2011
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trialG Viale, M M Regan, P Dell'Orto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2011
Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane studyJudith M Bliss, Lucy S Kilburn, Robert E Coleman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2008
Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trialDiana Crivellari, Zhuoxin Sun, Alan S Coates, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 16, 2007
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trialL Mauriac, A Keshaviah, M Debled, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2007
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98Alan S Coates, Aparna Keshaviah, Beat Thürlimann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancerMartin R Stockler, Vernon J Harvey, Prudence A Francis, et al.
Journal of Thrombosis and Haemostasis : JTH|July 9, 2021
Remote history of VTE is associated with severe COVID-19 in middle and older age: UK Biobank cohort studyJana J Anderson, Frederick K Ho, Claire L Niedzwiedz, et al.
British Journal of Cancer|April 20, 2016
Adjuvant ovarian function suppression and cognitive function in women with breast cancerKelly-Anne Phillips, Meredith M Regan, Karin Ribi, et al.
Pageof 31